ArticleFrontiers in immunology2025
Expression characteristics, prognostic value, and immune-related analysis of PPP2R1A in lung adenocarcinoma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of PPP2R1A variants in gynecologic malignancies: a paradigm shift in immuno-oncology.Journal of translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lung adenocarcinoma (LUAD) is a major subtype of lung cancer with poor prognosis. The protein phosphatase 2 regulatory subunit A alpha (PPP2R1A) plays complex roles in tumorigenesis, but its function and clinical significance in LUAD remain unclear. Methods: We analyzed PPP2R1A expression across cancers using the Xiantao Academic Online tool and TCGA data. Diagnostic potential was evaluated via ROC curve analysis. Prognostic value was assessed using Kaplan-Meier survival and Cox regression analyses. Protein-protein interaction networks and functional enrichment analyses were conducted to explore molecular mechanisms. Immune infiltration patterns were investigated using TIMER2.0. Experimental validation was performed through CRISPR/Cas9-mediated knockdown in A549 cells, followed by functional assays including CCK-8, clonogenic, wound healing, and Transwell assays. Results: PPP2R1A was significantly upregulated in LUAD tissues compared to normal controls (P < 0.05). It demonstrated modest diagnostic value with an AUC of 0.593. High PPP2R1A expression was associated with poor progression-free survival (FP) and overall survival (OS), particularly in early-stage disease. PPP2R1A expression correlated with advanced N stage and tumor stage. Functional enrichment analysis revealed involvement in protein dephosphorylation, cell cycle regulation, and metabolic pathways. Immune infiltration analysis showed significant correlations with macrophage and CD4+ T cell infiltration. Experimental validation confirmed that PPP2R1A knockdown significantly inhibited LUAD cell proliferation, migration, and invasion (P < 0.01). Discussion: PPP2R1A is overexpressed in LUAD and associated with poor prognosis, potentially serving as an oncogene by regulating key signaling pathways and immune microenvironment. Its knockdown suppresses malignant phenotypes, highlighting its potential as both a prognostic biomarker and therapeutic target in LUAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.